A Real-World Comparison of Cardiovascular, Medical and Costs Outcomes in New Users of SGLT2 Inhibitors versus GLP-1 Agonists

To compare SGLT2 inhibitors and GLP-1 agonists on cardiovascular (CV) outcomes, treatment persistence/discontinuation, healthcare utilization and costs.

Source: Diabetes Research and Clinical Practice - April 9, 2021 Category: Endocrinology Authors: Insiya B Poonawalla, Andy T Bowe, Michael C Tindal, Yunus A Meah, Phil Schwab Source Type: research